Trials / Completed
CompletedNCT01437059
Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)
A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-PCS02 in subjects with Elevated LDL-Cholesterol (LDL-C).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALN-PCS02 | Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion |
| DRUG | Sterile Normal Saline (0.9% NaCl) | Calculated volume to match active comparator |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-03-01
- Completion
- 2012-09-01
- First posted
- 2011-09-20
- Last updated
- 2012-10-12
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01437059. Inclusion in this directory is not an endorsement.